Age Related Macular Degeneration (dry AMD) Study
IRB/UVa Tracking #: 16586
Principal Investigator: Yates Paul, A
Contact: Ashton Leone
Official Trial Title: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration
Compensation: No Compensation
The UVA Department of Ophthalmology is conducting a research study to test the safety and effectiveness of an investigational drug to treat dry eye associated with macular degeneration.
You may qualify for this study if:
1. You are between 55 – 85 years of age.
2. You have geographic atrophy (advanced dry macular degeneration (AMD)) in at least one eye
3. Your vision is between 20/20 – 20/400 in the study eye
4. You do NOT have wet AMD in the study eye
What is involved?
Participation includes approximately 8 study visits and 4 telephone calls over a 31 month period. Each study visit will last about 1-3 hours. The first 6 months of participation involves an observation period to determine eligibility for the study. Eligible participants will receive the study drug for 24 months.
For more information about this study please contact the Study Coordinator, Ashton Leone, at (434) 243-5737 or firstname.lastname@example.org or visit: http://www.clinicaltrials.gov/ct2/show/NCT1342926?term=gsk+geographic+atrophy&rank=1 or www.dryamdstudy.com.
The principal investigator is Paul Yates, MD, PhD.